Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Research programme: cancer and inflammatory disorder therapeutics - Coegin Pharma

Drug Profile

Research programme: cancer and inflammatory disorder therapeutics - Coegin Pharma

Alternative Names: AVX 002; AVX 003; AVX 235; AVX 420; AVX 440; AVX 449

Latest Information Update: 01 Oct 2019

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Avexxin
  • Developer Coegin Pharma
  • Class Small molecules
  • Mechanism of Action Immunomodulators; Phospholipase A2 modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes
  • Available For Licensing Yes

Highest Development Phases

  • Preclinical Cancer
  • No development reported Glomerulonephritis; Rheumatoid arthritis

Most Recent Events

  • 01 Oct 2019 Avexxin is now called Coegin Pharma
  • 04 Nov 2017 No recent reports of development identified for preclinical development in Glomerulonephritis in Norway
  • 04 Nov 2017 No recent reports of development identified for preclinical development in Rheumatoid-arthritis in Norway
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top